Physician profile
Anne Shrout
NPI 1376526582
$5,847.82
in general payments reported to CMS, 2019-2025
34 companies · $398 in 2025
The $398 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $737 · 2020: $944 · 2021: $1,441 · 2022: $1,029 · 2023: $734 · 2024: $563 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,695.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,443.99 | 2019-2024 | Orilissa, Lo Loestrin Fe, Liletta |
| Pfizer INC. | $579.07 | 2019-2023 | |
| Therapeuticsmd, INC. | $566.40 | 2019-2022 | |
| Astellas Pharma US INC | $412.34 | 2019-2025 | Veozah |
| Amgen INC. | $367.09 | 2019-2025 | Evenity, Prolia, Prolia |
| Mayne Pharma Commercial LLC | $255.54 | 2021-2025 | |
| Allergan, INC. | $253.07 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $249.33 | 2019-2024 | Gardasil 9, Gardasil |
| Mylan Pharmaceuticals INC. | $193.00 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $188.04 | 2023-2025 | Myfembree, Gemtesa |
| Exeltis, USA INC. | $184.70 | 2021-2025 | Slynd |
| Millicent US INC | $166.23 | 2019-2025 | Femlyv, Femring, Intrarosa |
| Coopersurgical, INC. | $146.03 | 2019-2024 | Paragard T 380a, Endosee |
| Aspira Women'S Health INC | $107.03 | 2021-2022 | |
| Myriad Women'S Health, INC. | $100.50 | 2023 | Myrisk |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $80.95 | 2021-2022 | |
| Daiichi Sankyo INC. | $75.70 | 2020-2023 | Injectafer |
| Avion Pharmaceuticals | $69.63 | 2020-2021 | |
| Myovant Sciences INC. | $53.26 | 2021-2022 | |
| Exact Sciences Corporation | $44.77 | 2024 | Cologuard Collection Kit |
| Cumberland Pharmaceuticals, INC. | $34.91 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $32.88 | 2019-2020 | |
| Gilead Sciences, INC. | $31.98 | 2025 | |
| Shield Therapeutics INC | $27.64 | 2024 | |
| Duchesnay USA Incorporated | $23.51 | 2019 | |
| Vertical Pharmaceuticals, LLC | $20.93 | 2019 | |
| Sage Therapeutics, LLC | $20.24 | 2023 | |
| Kerecis Limited | $19.34 | 2022 | |
| Lupin INC. | $19.29 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.00 | 2020 | |
| Axonics, INC. | $17.94 | 2024 | Axonics |
| Amag Pharmaceuticals, INC. | $16.76 | 2019 | |
| Agile Therapeutics, INC. | $14.32 | 2022 | |
| Meditrina | $12.41 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Shrout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.